Loading…
APLM
Apollomics Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP G0411D123
$26.60+7.09%Price as of Aug 29, 18:46 UTC · updated once a day, after the close
Key metrics
- Market cap
- $77.04M
- P/E
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- Payout
- —
- EPS
- -$7.57
- ROE
- -1305.37%
- Profit margin
- -123.72%
- Revenue growth
- —
- Beta
- 1.45
- 52-week high
- $42.12
- 52-week low
- $3.94
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -97.7% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $18.69 | $9.75 | $96.50 | $1,036.00 | |
| P/S | — | 4.7x | — | — | — |
| P/B | — | — | 2.2x | 2.1x | — |
| EPS | — | -$52.80 | -$231.99 | -$2.99 | |
| Profit margin | — | -128.69% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| GANXGain Therapeutics, Inc. | $1.77 | — | 6.8x | — | -268.30% | $77.25M |
| CINGCingulate Inc. | $5.33 | — | 3.2x | — | -198.74% | $77.44M |
| OSTXOS Therapies Inc | $1.64 | — | — | — | — | $76.21M |
| TELOTelomir Pharmaceuticals, Inc. | $1.14 |
About the company
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.
- 14
- Foster City, United States
Company description provided by Yahoo Finance.